Companies: 10,795·Total market cap: $144.5T

Yubo International Biotech Limited

Yubo International Biotech Limited

YBGJOTCHealthcare● Active

$0.01

+$0.00(+0.00%)

Market Cap$1006454

P/E Ratio—

52W High$0.1776

52W Low$0.0079

Avg Volume2K

Open$0.01

Beta0.64

Net Income Financials Revenue

Yubo International Biotech Limited (YBGJ) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

YBGJ · net income · updated Jun 15, 2026

Core profitability metrics

YBGJ · net income · margin · TTM · CAGR

Net income was −$1.1M for FY2025 (fiscal year ending 2025-12-31), up 39.2% year-over-year. Net profit margin was -803.1%.

FY2025 Net Income−$1.1M▲ +39.2% YoY

Trailing 12M (TTM)−$916,226trailing 4 quarters sum

Net Profit Margin-803.1%−$1.1M ÷ $134,391

YoY Change+39.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 15, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · YBGJ net income history · YBGJ profit margin

Annual net income data

YBGJ · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$1.1M▲ +39.2%-803.1%$134,391

FY2024Loss−$1.8M▼ 47.4%-51161.5%$3,470

FY2022Loss−$1.2M▲ +21.9%-1155.3%$104,283

FY2021Loss−$1.5M▼ 116.6%-123.9%$1.2M

FY2020Loss−$711,804▼ 380.9%-52.6%$1.4M

Net income vs peers (Healthcare)

YBGJ vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Yubo International Biotech LimitedYOU

YBGJ

−$1.1M+39.2%-803.1%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Yubo International Biotech Limited (YBGJ) reported net income of −$1.1M for FY2025 (fiscal year ending 2025-12-31), up 39.2% year-over-year. The net profit margin was -803.1% — meaning the company kept $-8.03 of every dollar of revenue as profit.

Yubo International Biotech Limited has not yet achieved annual profitability based on available data (15 fiscal years). The company has reported net losses across all available periods.

Yubo International Biotech Limited's net profit margin was -803.1% for FY2025, based on the latest annual results.

Investors sometimes search for "Yubo International Biotech Limited net worth" — the company's market capitalization is a separate figure from YBGJ net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

YBGJ net income · 4 questions

Yubo International Biotech Limited is not currently profitable on an annual basis. The company reported a net loss of $1.1M for FY2025.

is YBGJ profitabledoes YBGJ make a profitYBGJ profitabilityYBGJ profitable company

▸ Source: FMP /income-statement · GAAP · Yubo International Biotech Limited · Yubo International Biotech Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026